Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot proof-of-concept study of ravulizumab in corticosteroid-resistant idiopathic IgA nephropathy flares
2021-005609-28Phase 4Active
- Sponsor
- Dr. Alfons Segarra Medrano
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ravulizumab in IgA nephropathy (IgAN), sponsored by Dr. Alfons Segarra Medrano. Primary endpoints: Primary: Quantitative reduction of proteinuria at 26 weeks and Primary: Quantitative reduction of haematuria at 26 weeks. Started Jan 2022; status: active.
02
Drugs
ravulizumab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2021-005609-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005609-28.